

Oral toxic exposure of titanium dioxide nanoparticles on serum biochemical changes in adult male Wistar rats

Dasal Vasantharaja^{1*}, Venugopal Ramalingam¹, Gaddam Aadinaath Reddy²

¹Department of Zoology, Kanchi Mamunivar Centre for Post Graduate Studies, Puducherry, India

²Department of Pharmacology, Siddha Central Research Institute, Chennai, India

Abstract

Objective(s): Titanium dioxide (TiO₂) nanoparticles (NPs) are widely used in commercial food additives and cosmetics worldwide. Uptake of these nanoparticulate into humans by different routes and may exhibit potential side effects, lags behind the rapid development of nanotechnology. Thus, the present study designed to evaluate the toxic effect of mixed rutile and anatase TiO₂ NPs on serum biochemical changes in rats.

Materials and Methods: In this study, adult male Wistar rats were randomly allotted into the experimental and control groups (n=6), which were orally administered with 50 and 100 mg/kg body weight of TiO₂ NPs. Toxic effects were assessed by the changes of serum biochemical parameters such as glucose, total protein, albumin, globulin, cholesterol, triglyceride, high density lipoprotein, alanine transaminase, aspartate transaminase, alkaline phosphatase, total bilirubin, blood urea nitrogen, uric acid and creatinine. All the serum biochemical markers were experimented in rats, after 14-days of post exposure.

Results: Changes of the serum specific parameters indicated that liver and kidney were significantly affected in both experimental groups. The changes between the levels of total protein, glucose, aspartate transaminase, alanine transaminase and alkaline phosphatase indicate that TiO₂ NPs induces liver damage. Significant increase in the blood urea nitrogen and uric acid indicates the renal damage in the TiO₂ NPs treated rats.

Conclusion: The data shows that the oral administration of TiO₂ NPs (<100nm) may lead to hepatic and renal toxicity in experimental rats.

Keywords: Nanoparticle, Oral toxicity, Serum biochemical markers, Titanium dioxide, Wistar rat

*Corresponding Author: Dasal Vasantharaja, Department of Zoology, Kanchi Mamunivar Centre for Post Graduate Studies, Puducherry, India.
Tel: +91 9751679545, E-mail: vasaini20@gmail.com

Introduction

Nanotechnology is a major innovative and highly hopeful technology in the field of molecular science, which may use in medical, agriculture, industrial, manufacturing and military sectors (1, 2). The basic principle of the nanotechnology has resulted in a reduction of particle sizes, which improves cellular uptake efficiencies and endows novel physical properties that are potentially useful in biomedical research (3, 4).

In recent years, titanium dioxide (TiO₂) nanoparticles (NPs) are consequently used in paints, plastics, papers, ink, cosmetics and skin care products especially in the case of 1-100 nm size (5-9).

However, it has unique characteristics such as small size, large surface per unit mass and high reactivity that NPs can quickly enter the human body and then imposes potential health risk on human welfare (10, 11).

The ultra-sized TiO₂ particles enable them to pass through cell membranes to nuclear membranes; finally they can interrupt on cell ultrastructure and damage the cell membrane (12, 13). TiO₂ is a preferred nanomaterial for experimentalists because it has been used as negative controls in toxicity screening studies as well as suited for low solubility and low toxicity (14-16). The toxic proof of the TiO₂ NPs exposure leads to adverse effects in aquatic organisms also; this was confirmed by Linhua et al (17).

TiO₂ NPs have two major forms of crystal structures, named rutile and anatase. Both are toxic but the anatase NPs may produce much more toxic than rutile NPs and these particles mutually associated with oxidizing mechanisms of an organism, which capable of generating ROS (18) including oxidative stress and DNA damage (19-23).

Humans are highly exposed to TiO₂ NPs because of its extensive area of use. Liver is most vulnerable target organs of those NPs, which act as detoxification of the body. Most of the terrestrial activities, oral

uptake of manufactured NPs to human has become so common because those particles are used as color additive for food as well as tooth paste and capsule (24).

In toxicological studies of an acute exposure to NPs, the changes of specific enzyme levels which directly reflects the damage in specific cells and organs (12, 25).

TiO₂ NPs formulated products are easily enter into the human body via different routes with different forms and may interrupt the body metabolism. Until now, most of the toxicological studies of TiO₂ NPs in mammalian models have focused on the hepatotoxicity via inhalation or dermal exposure.

Therefore, the present study is aimed to investigate the toxic effects of mixed rutile and anatase TiO₂ NPs (<100 nm) on *in-vivo* model through repeated oral administration of adult male Wistar rats.

Materials and Methods

Nanomaterials and preparation of treated suspension

Fully characterized mixture of rutile and anatase TiO₂ NPs used in the present study was purchased from Sigma-Aldrich chemicals Co. (St, Louis, MO 63103, USA). Characterization of the TiO₂ NPs as follows: a mixture of rutile and anatase nanopowder, appearance- color-white, powder form with particle size <100 nm and its purity 99.5 % trace metal basis. NPs were suspended in 0.9% saline and that suspension was sonicated for 10 min before the treatment.

Experimental animals and treatment

Adult male Wistar rat strains (*Rattus norvegicus*) weights (240-260g) were used in this study. Animals were housed in polypropylene cages placed in ventilated animal house (Siddha Central Research Institute, Chennai, Tamil Nadu, India). Temperature, humidity and 12 hours light/dark cycle were properly maintained. Distilled water and commercial food pellets for rats were available *ad libitum*.

They were acclimatized for five days prior to the experiment. All procedures were followed as per Institutional Animal Ethical Committee (IAEC) (138/PHARMA/SCRI, 2013).

Animals were randomly divided into three groups, each group containing six rats (n=6): Control group treated with 0.9 % saline only and the experimental groups treated with TiO₂ NPs suspension (50 and 100 mg/kg of body weight) administered orally through intragastric oral intubation tube for 14 consecutive days. On the 15th day all animals were sacrificed using cervical decapitation. The dose selection based upon the report of World Health Organization in 1969. According to the statement, LD₅₀ of TiO₂ for rats is more than 12,000 mg/kg body weight (b.w) after oral administration (26). The dose of 50 mg/kg (b.w) and 100 mg/kg (b.w) of TiO₂ NPs was selected for the present study and exposed to rats every day.

Serum biochemical analysis

Blood samples were collected by the method of ocular vein puncture.

Collected blood samples were allowed to coagulate and the serum part was harvested immediately and utilized for biochemical analysis like, Total protein (TP), Albumin (ALB), Globulin (GLB), Cholesterol (CHOL), Triglycerides (TG) and High density lipoprotein (HDL) were measured by commercially available kit (Siemens Healthcare Diagnostics Ltd.).

The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (TBILI) are estimate for liver functional test. Nephrotoxicity was determined by the levels of blood urea nitrogen (BUN), uric acid (UA) and creatinine (CREA) as well as glucose (GLU) levels was also measured in serum using by (Bayer RA-50, Auto-analyzer).

Statistical analysis

Statistical analysis of all data are expressed as mean \pm standard error mean (SEM) and also followed by a one-way analysis of variance (ANOVA).

The values of P<0.05 was considered as statistical significance. Statistical analysis was performed using SPSS (version 19) software package.

Results

In this study, the GLU values were significantly increased in both the experimental groups as compared with that of control. The GLU values were elevated with 50 mg/kg of TiO₂ NPs treated group and more significantly (P<0.01) increased with 100 mg/kg treated group (Table 1).

There was no significant difference in ALB, GLB, and TBILI, while the TP was decreased in the serum of 50 mg/kg experimental group, but slightly increased TP was observed from 100 mg/kg TiO₂ NPs treated group.

There was a significant elevation in the CHOL and decrease in TG value noted from both of the experimental groups.

HDL level was non-significant in 50 mg/kg group and steep elevation was found in the 100 mg/kg group compared with that of control.

The enzymes AST and ALP levels varied in the serum of both TiO₂ NPs treated groups. A remarkable decrease of ALP activity was observed from both groups. AST levels were significantly (P<0.05) increased in 100 mg/kg of TiO₂ NPs treated group, but not significantly increased in 50 mg/kg group.

There were no changes of ALT levels in both the experimental groups. The renal functional parameters of BUN and UA was increased in both the TiO₂ NPs intoxicated groups, while there were no change of CREA in the two experimental TiO₂ treated groups.

Oral toxicity of TiO₂ nanoparticles

Table 1. Changes of the serum biochemical parameters in TiO₂ NPs treated rats after 14-days oral supervision.

Parameters	Control	TiO ₂ NPs treated 50mg/kg (b.w)	TiO ₂ NPs treated 100mg/kg (b.w)
GLU(mg/dL)	106.83 ± 4.61	125.16 ± 4.33*	127.0 ± 3.043**
TP (g/dL)	7.83 ± 0.102	7.23 ± 0.200*	8.28 ± 0.153*
ALB (g/dL)	3.33 ± 0.122	3.25 ± 0.102	3.61 ± 0.134
GLB (g/dL)	4.50 ± 0.134	3.98 ± 0.261	4.40 ± 0.269
CHOL (mg/dL)	67.50 ± 4.12	84.33 ± 4.48*	101.16± 8.25**
TG (mg/dL)	191.5 ± 11.46	122.33 ±11.97**	122.83 ± 14.52**
HDL (mg/dL)	38.20 ± 1.056	39.60 ± 0.982	43.20 ± 1.59*
AST (U/L)	130.8 ± 4.48	134.00 ± 4.62	145.20 ± 4.14*
ALT (U/L)	57.20 ± 3.94	49.80 ± 3.95	56.60 ± 3.49
ALP (U/L)	244.0 ± 4.91	219.20 ± 4.70**	216.60 ± 4.92**
TBILI (mg/dL)	0.55 ± 0.093	0.56 ± 0.040	0.50 ± 0.024
BUN (mg/dL)	39.66 ± 1.85	46.50 ± 2.31*	48.16 ± 1.98*
UA (mg/dL)	1.08 ± 0.187	1.40 ± 0.163	1.61 ± 0.118*
CREA (mg/dL)	0.63 ± 0.032	0.61 ± 0.032	0.62±0.069

Note: Serum biochemical parameters are expressed as mean ± SEM values, *p<0.05, **p<0.01 significant difference from the groups (n=6/group).

Discussion

Generally, the impacts of TiO₂ NPs exposure have been experimented in different animals followed by different routes of administration including whole body and dermal exposure as well as gastric lavage and inhalation (27-29). In 1969, WHO reported that the LD₅₀ of TiO₂ for rats is more than 12,000 mg/kg (b.w) after oral administration (26). In this study, we selected 50 and 100 mg/kg (b.w) of rutile and anatase mixed TiO₂ NPs exposed rats for 14 consecutive days. Different epidemiological studies have shown those TiO₂ NPs is low toxic and no carcinogenic effects in human (30, 31).

But recently, the International Agency for Research on

Cancer (IARC) working group was classified the ultrafine TiO₂ particles as possibly carcinogenic to human (32). In our study, mixture of rutile and anatase TiO₂ NPs induced abnormal physiological activities in male rats with emphasis to liver and kidney. Previously, Jani *et al.* (1994) reported that orally ingested rutile TiO₂ NPs can be absorbed via the gastrointestinal tract and pass through the mesentery lymph supply and lymph node to the liver (33). The liver is activated to abolish the side effect induced by these particles. Recently, biodistribution studies

have examined that the ultrafine TiO₂ particles mostly accumulate in the liver followed by kidney and are excreted gradually (34, 35). However, the small size NPs are very difficult to clearance from the liver, resulted in long time retention and induced the liver damage after oral exposure of 5 g/kg TiO₂ NPs in mice (36). Previous studies also reported that the retention halftime of TiO₂ NPs *in vivo* was long because of its small size and very complicated to clearance. Furthermore, intravenously injected TiO₂ NPs on rats with the dose of 250 mg/kg were 69% accumulated in liver at after 5 min and at other hand 80% of particles accumulated in liver at after 15 min (37). In the present investigation oral ingestion of <100 nm TiO₂ NPs may deposit in the liver and leads to hepatic damage conformed by the fluctuations in hepatic marker enzymes ALT, AST and ALP and nephron-markers as while.

Since the liver is the major place for biological changes and it protect the body from foreign substances and xenobiotic chemicals, identifying the causes for hepatic toxicity. The liver excretes the substances into bile; consequently the biliary organism is also exposed to NPs. Previous study have shown that various toxins with diverse mechanisms, including activation of alcohol degeneration, membrane lipid peroxidation, inhibition of protein synthesis, disruption of calcium homeostasis and activation of receptor enzymes, cause damage to liver cells (11). Enzymes such as ALT and AST are the metabolic enzymes in liver, which are dysfunctional enzymes in serum and plasma. The level of these enzymes in the cytoplasm of liver cells is number of times more than extracellular fluid. When the hepatic cells and membrane are damaged or died, the amount of these enzymes raise in the blood stream and this amount of elevation is an indication of the liver damage (38, 39). In the present study, rats were exposed to different doses of TiO₂ NPs; resulted in significant difference

between the levels of AST and ALT enzymes within the groups. Although the levels of serum AST were increased in the TiO₂ NPs treated rats when compared to that of controls, this change was not significant in among the experimental groups. Wang et al (36), who reported that the TiO₂ NPs induce acute hepatic damage.

ALP is nothing but a cholestatic liver enzyme. Cholestasis is a state that causes partial or blockage of the bile ducts. Bile duct gives bile from the liver into the gall bladder and intestines. Bile is the fluid secreted from the liver cells helps the body to split the fat, process cholesterol and get free of toxins. If the bile duct is sore or injured, ALP can get backed up and leak out from the liver into the blood stream (40). In this study, reduced ALP and significantly elevated CHOL levels were observed in the serum of TiO₂ NPs treated rats. However, certain liver toxicity was monitored by the raise of CHOL in serum of male rats following the 28-days oral supervision of the low and high dose of silver NPs, and bile duct hyperplasia was observed in the male rats (41). Moreover, our findings records with elevated CHOL levels in the serum of male rats followed by low and high dose of TiO₂ NPs.

Nanoparticles are exposed to reach the systemic circulation after ingestion, inhalation or intravenous injection. They can share out to a number of organs such as liver, spleen, kidney, heart, brain, and ovary (11, 42-45). Meanwhile, kidney has been known to remove the unsafe substances from the blood, thus NPs absorb in to the circulatory system and can be filtered by renal system (46, 47). However, kidney dysfunction was found in rats treated with TiO₂ NPs, because of an increased level of BUN and UA in serum. In contrast, Wang *et al.* (2007) explained that the high levels of BUN and CREA in the serum of mice, which leads to dysfunction and pathological changes of kidneys (36). But the present study indicates there is no significant changes of

CR in the serum of TiO₂ NPs treated rats. On the other hand, the authors accomplished that TiO₂ NPs in higher dose caused severe damage to the liver and kidney and it troubled the equilibrium of blood glucose and lipid in mice (48). Furthermore, Meena and Paulraj(2012) were conformed in the increased levels of BUN in serum is directly associated with the sign of glomerulonephric toxicity, swelling in renal glomerulus, renal tubules crammed with the proteinic fluids because of the hold up of TiO₂ particles in kidneys, observed with 50 mg/kg TiO₂ NPs treated rats (49). Present study confirms, after oral administration of TiO₂ NPs have possible accumulation in the liver, and kidney which induce adverse side effects in the rats ingested with TiO₂NPs.

Conclusion

Present study reflects that TiO₂ NPs has adverse side effects in the physiological system in terms of hepatic and renal toxicity in TiO₂ NPs intoxicated rats. Oral administration of TiO₂ NPs may accumulate in the liver and kidney, which affects in lipid profile too. Hence, the usage of TiO₂ NPs and its formulated food and cosmetic commodity in day today life should be curiously focused in order to ascertain its toxic effects in humans.

Acknowledgments

Our heartfelt thanks to the Director Siddha Central Research Institute (SCRI), Chennai and the Director and Head department of Zoology, K.M Centre for PG Studies, Puducherry, for providing necessary lab facilities to carry out this study successfully. Our sincere thank to the staff members, Department of Pharmacology and Biochemistry, (SCRI) Chennai, for their technical support.

References

1. Robertson TA, Sanchez WY, Roberts MS. Are commercially available nanoparticles safe when applied to the skin? *J Biomed Nanotechnol.* 2010; 6: 452-468.
2. Kisin ER, Murray AR, Keane MJ, Shi XC, Schwegler-Berry D, Gorelik O, et al. Single-walled carbon nanotubes: geno- and cytotoxic effects in lung fibroblast V79 cells. *J Toxicol Environ Health A.* 2007; 70: 2071-2079.
3. Stark WJ. Nanoparticles in biological systems. *Angew Chem Int Ed.* 2011; 50: 1242-1258.
4. Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland JA, Byers RJ. Quantum dots light up pathology. *J Pathol.* 2008; 216: 275-285.
5. Brunet L, Lyon DY, Hotze EM, Alvarez PJ, Wiesner MR. Comparative photoactivity and antibacterial properties of C-60 fullerenes and titanium dioxide nanoparticles. *Environ Sci Technol.* 2009; 43: 4355-4360.
6. Nemmar A, Melghit K, Ali BH. The acute proinflammatory and prothrombic effects of pulmonary exposure to rutile TiO₂ nanorods in rats. *Exp Biol Med.* 2008; 233: 610-619.
7. Gelis C, Girard S, Mavon A, Delverdier M, Paillous N, Vicendo P. Assessment of the skin photoprotective capacities of an organo-mineral broad-spectrum sun block on two ex vivo skin models. *Photodermatol Photoimmunol Photomed.* 2003; 19: 242-253.
8. Lomer MC, Thompson RP, Powell JJ. Fine and ultrafine particles of the diet: Influence on the mucosal immune response and association with Crohn's disease. *Proc Nutr Soc.* 2002; 61: 123-130.
9. Linkous CA, Carter GJ, Locuson DB. Photocatalytic Inhibition of algae growth using TiO₂, WO₃ and co-catalyst modifications. *Environ Sci Technol.* 2000; 34: 4754-4758.
10. Warheit DB, Hoke RA, Finlay C, Donner EM, Reed KL, Sayes CM. Development of a base of toxicity tests using ultrafine TiO₂ particles as a component of nanoparticle risk management. *Toxicol Lett.* 2007; 171: 99-110.
11. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. *Environ Health Perspect.* 2005; 113(7): 823-839.
12. Moss OR, Wong VA. When nanoparticles get in the way: impact of projected area on in vivo and in vitro macrophage function. *Inhal Toxicol* 2006; 18(10): 711-716.
13. Moller W, Hofer T, Ziesenis A, Karg E, Heyder J. Ultrafine particles cause

- cytoskeletal dysfunctions in macrophages. *Toxicol Appl Pharmacol.* 2002; 182(3): 197-207.
14. Hext PM, Tomenson JA, Thompson P. Titanium dioxide: inhalation toxicology and epidemiology. *Ann Occup Hyg.* 2005; 49(6): 461-472.
 15. Bermudez E, Mangum JB, Asgharian B, Wong BA, Reverdy EE, Janszen DB, et al. Longterm pulmonary responses of three laboratory rodent species to subchronic inhalation of pigmentary titanium dioxide particles. *Toxicol Sci.* 2002; 70: 86-97.
 16. Donaldson K. Nonneoplastic lung responses induced in experimental animals by exposure to poorly soluble nonfibrous particles. *Inhal Toxicol.* 2000; 12(1-2): 121-139.
 17. Linhua H, Zhenyu W, Baoshan X. Effect of sub-acute exposure to TiO₂ nanoparticles on oxidative stress and histopathological changes in Juvenile Carp (*Cyprinus carpio*). *J Environ Sci.* 2009; 21: 1459-1466.
 18. Gurr JR, Wang AS, Chen CH, Jan KY. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. *Toxicol.* 2005; 213: 66-73.
 19. Falck GC, Lindberg HK, Suhonen S, Vippola M, Vanhala E, Catalan J, et al. Genotoxic effects of nanosized and fine TiO₂. *Human Exp Toxicol.* 2009; 28: 339-352.
 20. Wang JX, Fan YB, Gao Y, Hua QH, Wang TC. TiO₂ nanoparticles translocation and potential toxicological effect in rats after intra-articular injection. *Biomaterials.* 2009; 30: 4590-4600.
 21. Vamanu CI, Cimpan MR, Hol PJ, Sornes S, Lie SA, Gjerdet NR. Induction of cell death by TiO₂ nanoparticles: Studies on a human monoblastoid cell line. *Toxicol In Vitro.* 2008; 22: 1689-1696.
 22. Jeng HA, Swanson J. Toxicity of metal oxide nanoparticles in mammalian cells. *J Environ Sci Health Part A.* 2006; 41: 2699-2711.
 23. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. *Toxicol In Vitro.* 2005; 19: 975-983.
 24. FDA. Titanium dioxide. In *The United States Code of Federal Regulations, Title 21, Section 73.575*, 2005. Office of the Federal Register, Washington, DC.
 25. Shi H, Magaye R, Castranova V, Zhao J. Titanium dioxide nanoparticles: a review of current toxicological data. *Part Fibre Toxicol.* 2013; 10: 15.
 26. World Health Organization (WHO). *FAO Nutrition Meetings Report Series No. 46A: 1969. Toxicological evaluation of some food colours, emulsifiers, stabilizers, anti-caking agents and certain other substances.* WHO/ FOOD ADD/70.36.
 27. Bermudez E, Mangum JB, Wong BA, Asgharian B, Hext PM, Warheit DB, et al. Pulmonary responses of mice, rats, and hamsters to subchronic inhalation of ultrafine titanium dioxide particles. *Toxicol Sci.* 2004; 77: 347-357.
 28. Grassian VH, O'Shaughnessy PT, Adamcakova-Dodd A, Pettibone JM, Thorne PS. Inhalation exposure study of titanium dioxide nanoparticles with a primary particle size of 2 to 5 nm. *Environ Health Perspect.* 2007; 115: 397-402.
 29. Wang JX, Li YF, Zhou GQ, Li B, Jiao F, Chen CY, et al. Influence of intranasal instilled titanium dioxide nanoparticles on monoaminergic neurotransmitters of female mice at different exposure time. *Zhonghua Yu Fang Yi Xue Za Zhi.* 2007; 41(2): 91-95.
 30. Boffetta P, Soutar A, Cherie JW, Granath F, Anderson A, Anttila A, et al. Mortality among workers employed in the titanium dioxide production industry in Europe. *Cancer Causes Control.* 2004; 15: 697-706.
 31. Chen JL, Fayerweather WE. Epidemiologic study of workers exposed to titanium dioxide. *J Occup Med.* 1988; 30(12): 937-942.
 32. International Agency for Research on Cancer (IARC). Carbon black, titanium dioxide, and talc. In *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*. Lyon, France: World Health Organization, International Agency for Research on Cancer. 2010; 93: 1-452.
 33. Jani PU, Mc-Carthy DE, Florence AT. Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. *Int J Pharma.* 1994; 105: 157-68.
 34. Fabian E, Landsiedel R, Wiench K, Wohlleben W, Ravenzwaay BV. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. *Arch Toxicol.* 2008; 82: 151-157.
 35. Sugibayashi K, Todo H, Kimura E. Safety evaluation of titanium dioxide nanoparticles by their absorption and

Oral toxicity of TiO₂ nanoparticles

- elimination profiles. *J Toxicol Sci.* 2008; 33: 293-298.
36. Wang JX, Zhou GQ, Chen CY, Yu HW, Wang TC, Ma YM. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. *Toxicol Lett.* 2007; 168: 176-185.
 37. Huggins CB, Froehlich JP. High concentration of injected titanium dioxide in abdominal lymph nodes. *J Exp Med.* 1966; 124: 1099-1106.
 38. Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: Use of in vitro models. *J Toxicol Pathol.* 2005; 33: 17-26.
 39. Worth AP, Balls M. Alteration (non-animals) methods for chemical testing: Current status and future prospects. A report prepared by ECVAM and the ECVAM working group on chemicals, Alternative to laboratory animals (ATLA): 2002. P. 71-82.
 40. Popper H. Cholestasis. *Annu Rev Med.* 1968; 19: 39-56.
 41. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park JD, et al. Biopersistence of silver nanoparticles in tissues from Sprague-Dawley rats. *Part Fibre Toxicol.* 2013; 10: 36.
 42. Nemmar A, Hoet PH, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, et al. Passage of inhaled particles into the blood circulation in humans. *Circulation.* 2002; 105(4): 411-414.
 43. De-Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. *Biomaterials.* 2008; 29(12): 1912-1919.
 44. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhassetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. *Mol Pharmacol.* 2008; 5(2): 316-327.
 47. Burns AA, Vider J, Ow H, Herz E, Penate-Medina O, Baumgart M, et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. *Nano Lett.* 2009; 9(1): 442-448.
 48. Schipper ML, Iyer G, Koh AL, Cheng Z, Ebenstein Y, Aharoni A, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. *Small.* 2009; 5(1): 126-134.
 49. Gao GD, Ze YG, Li B, Zhao XY, Zhang T, Sheng L, et al. Ovarian dysfunction and gene-expressed characteristics of female mice caused by long-term exposure to titanium dioxide nanoparticles. *J Hazard Materials.* 2012; 243: 19-27.
 50. Liu R, Yin L, Pu Y, Liang G, Zhang J, Su Y, et al. Pulmonary toxicity induced by three forms of titanium dioxide nanoparticles via intratracheal instillation in rat. *Prog Nat Sci.* 2009; 573-579.
 52. Meena R, Paulraj R. Oxidative stress mediated cytotoxicity of TiO₂ nano anatase in liver and kidney of Wistar rat. *Toxicol Environ Chem.* 2012; 94(1): 146-16146-163.